Amarin stock analysis
Want to see AMRN full AI Analyst Report?
Amarin (AMRN) Stock Price & Analysis
AMRN Stock Chart & Stats
- Day’s Range
- $11.18 - $11.36
- 52-Week Range
- $11.15 - $17.31
- Previous Close
- $11.27
- Volume
- N/A
- Average Volume (3M)
- 77.62K
- Market Cap
- $237.38M
- Enterprise Value
- -$40.12M
- Total Cash (Recent Filing)
- $323.38M
- Total Debt (Recent Filing)
- $7.61M
- Price to Earnings (P/E)
- ―
- Beta
- 1.41
- Next Earnings
- Mar 03, 2027 (Est.)
- EPS Estimate
- -0.08
- Next Dividend Ex-Date
- N/A
- Dividend Yield
- N/A
Bulls Say, Bears Say
Bulls Say
Debt-free Balance Sheet And Cash Generation
Very low leverage and recently positive operating cash flow give Amarin financial flexibility while the business stabilizes. The cash cushion can support commercialization, partnerships, and operating needs without refinancing pressure, although continued cash generation remains important.
Sustained International Demand Growth
Sustained international demand growth provides an important counterweight to U.S. pressure and broadens the company’s commercial base. Continued partner-led expansion, including upcoming Asian launches, could increase geographic diversification and improve long-term product utilization.
Lower Structural Cost Base
A materially lower operating expense base improves the economics of Amarin’s commercialization model and reduces the revenue required to approach profitability. If these savings persist, they can support cash generation and partially offset pricing pressure even without substantial sales growth.
Bears Say
Multi-year Revenue And Margin Pressure
Shrinking revenue indicates that Amarin has not yet stabilized the scale of its core business, while negative operating and net margins show that cost discipline has not produced durable profitability. This limits internal reinvestment capacity and keeps earnings recovery dependent on execution.
Ongoing U.S. Pricing Pressure
Lower U.S. net pricing directly pressures revenue quality and gross profit, even where branded volume is stable. Management expects pricing pressure to continue into 2027, creating a durable headwind that may offset international growth and constrain the product’s earnings contribution.
Dependence On A Single Flagship Product
Reliance on VASCEPA/VAZKEPA concentrates commercial, regulatory, reimbursement, and competitive exposure in one product franchise. Any sustained change in demand, pricing, payer access, or partner execution could therefore affect most of Amarin’s revenue and cash generation.
Amarin News
AMRN FAQ
What was Amarin’s price range in the past 12 months?
What is Amarin’s market cap?
When is Amarin’s upcoming earnings report date?
How were Amarin’s earnings last quarter?
Is Amarin overvalued?
Does Amarin pay dividends?
What is Amarin’s EPS estimate?
How many shares outstanding does Amarin have?
What happened to Amarin’s price movement after its last earnings report?
Which hedge fund is a major shareholder of Amarin?
What is the TipRanks Smart Score and how is it calculated?
Amarin Stock Smart Score
Company Description
Amarin
Amarin Corporation plc is a pharmaceutical firm dedicated to the research, development, and commercialization of therapeutic solutions for cardiovascular diseases. Its operations span several international regions, including the United States, Germany, Canada, Lebanon, and the United Arab Emirates. The company's flagship product is VASCEPA, an omega-3 fatty acid formulation available by prescription only. This medication acts as an adjunctive therapy to diet, designed to decrease elevated triglyceride levels in adult patients suffering from severe hypertriglyceridemia. Amarin primarily distributes its offerings through wholesale channels and specialized pharmacy providers. Furthermore, the company has entered into a collaboration with Mochida Pharmaceutical Co., Ltd. to advance the development and market introduction of drug products and new indications derived from Vascepa's active pharmaceutical ingredient, which encompasses omega-3 acid and eicosapentaenoic acid. Established in 1989 as Ethical Holdings plc, the organization rebranded to Amarin Corporation plc in 1999. Its corporate headquarters are located in Dublin, Ireland.
- Sector
- Healthcare
- Industry
- Drug Manufacturers - General
- CEO
- Aaron D. Berg
- Employees
- 80
- Website
- www.amarincorp.com
- Address
- One Central Plaza, Dublin, DU, D02 K7K5, IE
Amarin (AMRN) Earnings & Revenues
AMRN Company Deck
AMRN Earnings Call
Earnings Call SentimentPositive
The call was predominantly positive, supported by the first profitable quarter in two years, four consecutive quarters of positive operating cash flow, a stronger debt-free balance sheet, lower expenses, improving supply economics, strong international in-market demand growth, maintained U.S. market leadership, and encouraging overall survival data from EMT2. These positives were tempered by lower total and U.S. revenue, continued U.S. pricing pressure, lower European product revenue, variability in partner ordering, uncertainty around 2027 exclusivity, and EMT2's failure to meet its primary progression-free survival endpoint.
View all AMRN earnings summariesAMRN Stock 12 Month Forecast
Average Price Target
Technical Analysis
Overall Consensus
| Indicator | Bullish | Neutral | Bearish |
|---|---|---|---|
| Overall Consensus | 5 | 3 | 14 |
| Technical Analysis | 5 | 3 | 2 |
| Moving Averages | 0 | 0 | 12 |











